PeerConnect


photo

Winny Tan - Analyst Profile

Industry Analyst
Frost & Sullivan
Healthcare

Summary

13 years as a Strategic Advisor and Business Developer. Skilled in:

  • Market research methods: Primary and secondary research, Voice-of-customer survey, KOL interview, databases.
  • Data analysis and programs: Advanced excel, biostatistics, SQL.
  • Consultative sales cycle: Lead generation, business development, proposal writing, deal closing.

Expert in global in vitro diagnostics, physician adoption, and global healthcare trends.

  • Clinical diagnostics, reference labs, and hospital labs.
  • Specialty diagnostics: Cancer diagnostics, prenatal testing, clinical genomic testing.
  • Consulted on and presented custom deliverables for M&A, market demand, product development, growth forecasts, customer satisfaction, market positioning.

What I bring to the Team

  • Strong ability to lead teams and delivering results that exceed expectations.
  • Data-driven recommendations with high levels of confidence.
  • A can-do attitude and ability to scope concrete solutions to open-ended problems.

Career Highlights

  • Invited speaker to pharma and IVD industry conferences and podcasts
  • Published opinion articles in Genetic Engineering & Biotechnology News, Drug Discovery News, Drug Development and Discovery
  • Multiple Frost & Sullivan employee awards recognizing above-and-beyond performance and selection into Star Analyst Program
  • Co-founded a personalized cancer diagnostics start-up company
  • Scientific manuscript reviewer for Sensors & Actuators B. Chemical and Journal of the Association for Laboratory Automation
  • Ph.D. research was listed in Popular Mechanics list of 20 Biotech Breakthroughs That Will Change Medicine.

Education

Ph.D. in Biomedical Engineering from UCLA, Los Angeles


Recent items from Winny Tan

This issue of Vital Signs, released on February 28, 2014, discusses three M&A transactions this month by Nestle, Myriad Genetics, and Fludigm' and what these deals mean for the industry. Additionally, Illumina's first stab at personalized medicine through a partnership with Amgen is explored.
Published: Feb 28 2014 Market Insights
Published: Feb 04 2014 Best Practices
This issue of Vital Signs, released on January 17, 2014, discusses perspectives of different Frost & Sullivan analysts on recent noteworthy news items for our core markets including Pharma/Biotech, In Vitro Diagnostics, Advanced Medical Technology, and Connected Health.
Published: Jan 17 2014 Market Insights
This issue of Vital Signs, released on November 22, 2013, provides overview of global IVD market dynamics, discuss growth strategy, and explore early opportunities in the African IVD market. Additionally, a company spotlight is provided for Global BioDiagnostics based in Temple, Texas. The company is focused on developing affordable diagnostic tests with the mission to improve global health and have developed a point-of-care diagnostic for tuberculosis.
Published: Nov 22 2013 Market Insights
This issue of Vital Signs, released on October 31, 2013, discusses perspectives of different Frost & Sullivan analysts on recent noteworthy news items for various markets including Pharma/Biotech, In Vitro Diagnostics, and Advanced Medical Technology.
Published: Oct 31 2013 Market Insights
This issue of Vital Signs, released on September 30, 2013, discusses perspectives of different Frost & Sullivan analysts on recent noteworthy news items for various markets including Pharma/Biotech, In Vitro Diagnostics, Advanced Medical Technology and Connected Health.
Published: Sep 30 2013 Market Insights
Source: Alere Press Release; August 9, 2013 Alere announced that it has received approval from the U.S. Food and Drug Administration (FDA) for its DetermineTM HIV-1 and HIV-2 Ag/Ab Combo rapid diagnostic test. The company reports that this is the first FDA approved point-of-care test (POCT) that detects both HIV-1/2 antibodies and the HIV-1 p24 an...
18 Sep 2013 Blog post
This issue of Vital Signs, released on August 31, 2013, discusses perspectives of different Frost & Sullivan analysts on recent noteworthy news items for various markets including Pharma/Biotech, Advanced Medical Technology and Connected Health.
Published: Aug 31 2013 Market Insights
This issue of Vital Signs, released on July 31, 2013, discusses perspectives of different Frost & Sullivan analysts on recent noteworthy news items for various markets including Pharma/Biotech, In Vitro Diagnostics, Advanced Medical Technology and Connected Health.
Published: Jul 31 2013 Market Insights
Published: Jul 26 2013 Best Practices
Source: Leica Biosystems News Release; July 9, 2013 and News Release; April 24, 2013 Anatomic pathology player, Leica Biosystems, a division of Leica Microsystems, makes 2 strategic acquisitions within 3 months: fluorescent in situ hybridization (FISH) probe supplier Kreatech Diagnostics based in the UK and Aotec, Leica’s histopathology and micros...
17 Jul 2013 Blog post
This issue of Vital Signs published June 30, 2013, provides a global overview of market trends and expected growth of the Point-of-care Testing (POCT) market.
Published: Jun 30 2013 Market Insights

Winny's Tweets

Help Desk

Full list of offices


For more information and general enquiries, contact Frost & Sullivan near you.

North America
tel: +1.877.463.7678

Select a location near you..